These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 30370642)
1. PDUFA VI: It Is Time to Unleash the Full Potential of Model-Informed Drug Development. Jain L; Mehrotra N; Wenning L; Sinha V CPT Pharmacometrics Syst Pharmacol; 2019 Jan; 8(1):5-8. PubMed ID: 30370642 [No Abstract] [Full Text] [Related]
2. PDUFA V goes back to basics. Mullard A Nat Rev Drug Discov; 2012 Aug; 11(8):586-8. PubMed ID: 22850772 [No Abstract] [Full Text] [Related]
3. Speed, Safety, and Industry Funding - From PDUFA I to PDUFA VI. Darrow JJ; Avorn J; Kesselheim AS N Engl J Med; 2017 Dec; 377(23):2278-2286. PubMed ID: 29211663 [No Abstract] [Full Text] [Related]
4. Regulatory watch: impact of PDUFA on regulatory decision-making. Hay M Nat Rev Drug Discov; 2010 Aug; 9(8):585. PubMed ID: 20671755 [No Abstract] [Full Text] [Related]
6. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
7. Pharmaceuticals and medical devices: FDA oversight. ; Berry MD Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845 [No Abstract] [Full Text] [Related]
8. Tort claims and federal regulation of medical devices vs pharmaceuticals. Green M JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694 [No Abstract] [Full Text] [Related]
9. Regulatory experts debate FDA's authority. Young D Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140 [No Abstract] [Full Text] [Related]
10. The federal preemption debate in pharmaceutical labeling product liability actions. Gross JM; Curry JA Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866 [No Abstract] [Full Text] [Related]
11. Congress, the FDA, and the fair development of new medications for children. McKinney RE Pediatrics; 2003 Sep; 112(3 Pt 1):669-70. PubMed ID: 12949299 [No Abstract] [Full Text] [Related]
12. Safe drugs and the cost of good intentions. Eichler HG; Abadie E; Raine JM; Salmonson T N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718 [No Abstract] [Full Text] [Related]
13. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]
14. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health. Gostin LO JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642 [No Abstract] [Full Text] [Related]
15. Pharmaceuticals and medical devices: FDA oversight. Issue brief. Berry MD Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449 [No Abstract] [Full Text] [Related]
16. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage? Roman A Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322 [No Abstract] [Full Text] [Related]
17. Pharmaceuticals and medical devices: business practices. Issue brief. Steiner DJ Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448 [No Abstract] [Full Text] [Related]
18. 1992 Le Tourneau Award. Problems with pharmaceutical regulation in the United States. Drug lag and orphan drugs. Henry V J Leg Med; 1993 Dec; 14(4):617-39. PubMed ID: 8308452 [No Abstract] [Full Text] [Related]
19. The application of the patent laws to the drug approval process. Coggio BD; Cerrito FD Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669 [No Abstract] [Full Text] [Related]
20. The Orphan Drug Act Revisited. Thomas S; Caplan A JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155 [No Abstract] [Full Text] [Related] [Next] [New Search]